Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Autologous stem cell therapy has been shown to be effective in patients with systemic sclerosis. Nevertheless treatment is associated with treatment related mortality and patients die during follow up despite successful transplantation.
Intention of this trial is to improve overall survival by modifying the existing protocol used for the ASTIS trial.
To reduce treatment toxicity we reduce the dose of Cyclophosphamide (CYC) for mobilisation to 2x1g.
Especially in patients with cardiac manifestations we also modify the conditioning regimen by adding thiotepa and reducing CYC; as CYC has known cardiotoxic side effects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Conditioning with CYC/ antithymocyte globulin (ATG) | Experimental | Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG |
|
| Conditioning with CYC/Thiotepa/ATG | Experimental | In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells | Drug | If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG |
| Measure | Description | Time Frame |
|---|---|---|
| Efficay - Overall survival | Number of patients that are alive after 3 years | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Safety - Treatment related mortality | Treatment related mortality: number of patients who die during the first 100 days after transplantation | 100 days |
| Time to engraftment | Time in days from day 0 to platelet count > 20.000 and granulocytes >500/µl |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy - Patient reported outcome | Differences in Health Assessment Questionnaire (HAQ) | 3 years |
Inclusion Criteria:
Diagnosis of progressive systemic sclerosis <7 years
Progressive course despite cyclophosphamide pretreatment
Cyclophosphamide i.v.: at least 3 x with 500-1000 mg/m² every 3-4 weeks or
Cyclophosphamide p.o. with at least 100mg/day for at least 2 months or
Contraindication to treatment with cyclophosphamide
Progress defined as at least one of the following criteria:
Limited or diffuse cutaneous progressive form of Ssc with organ manifestation in the lungs/heart or kidneys
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joerg C Henes, MD | University Hospital Tuebingen, Department of oncology, hematology, rheumatology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology | Tübingen | 72076 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24459219 | Derived | Henes JC, Koetter I, Horger M, Schmalzing M, Mueller K, Eick C, Bauer A, Vogel W, Kanz L. Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology (Oxford). 2014 May;53(5):919-22. doi: 10.1093/rheumatology/ket464. Epub 2014 Jan 22. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D045743 | Scleroderma, Diffuse |
| ID | Term |
|---|---|
| D012595 | Scleroderma, Systemic |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000943 | Antigens, Differentiation |
| ID | Term |
|---|---|
| D000954 | Antigens, Surface |
| D000941 | Antigens |
| D001685 | Biological Factors |
| D015415 | Biomarkers |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 2 months |
| Progression free survival | Time after transplantation without symptoms of disease activity | 3 years |
| Efficacy - Lung function test and Skin | Number of patients that achieve either improvement of >25% in mRSS or > 10% in FVC or DLCO | 3 years |